Purple Biotech Stock Working Capital
PPBT Stock | USD 0.51 0.01 1.92% |
Purple Biotech fundamentals help investors to digest information that contributes to Purple Biotech's financial success or failures. It also enables traders to predict the movement of Purple Stock. The fundamental analysis module provides a way to measure Purple Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Purple Biotech stock.
Purple |
Purple Biotech Company Working Capital Analysis
Purple Biotech's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Purple Biotech Working Capital | 8.61 M |
Most of Purple Biotech's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Purple Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition |
Based on the company's disclosures, Purple Biotech has a Working Capital of 8.61 M. This is 97.98% lower than that of the Biotechnology sector and 98.4% lower than that of the Health Care industry. The working capital for all United States stocks is 99.42% higher than that of the company.
Purple Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Purple Biotech's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Purple Biotech could also be used in its relative valuation, which is a method of valuing Purple Biotech by comparing valuation metrics of similar companies.Purple Biotech is currently under evaluation in working capital category among related companies.
Purple Fundamentals
Return On Equity | -0.49 | ||||
Return On Asset | -0.28 | ||||
Current Valuation | 124.49 M | ||||
Shares Outstanding | 26.11 M | ||||
Shares Owned By Insiders | 3.85 % | ||||
Shares Owned By Institutions | 8.19 % | ||||
Number Of Shares Shorted | 297.21 K | ||||
Price To Book | 0.47 X | ||||
Price To Sales | 58.08 X | ||||
Gross Profit | (120 K) | ||||
EBITDA | (22.07 M) | ||||
Net Income | (19.88 M) | ||||
Cash And Equivalents | 36.02 M | ||||
Cash Per Share | 2.00 X | ||||
Total Debt | 351 K | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 6.94 X | ||||
Book Value Per Share | 0.14 X | ||||
Cash Flow From Operations | (19.23 M) | ||||
Short Ratio | 1.30 X | ||||
Earnings Per Share | (0.90) X | ||||
Target Price | 9.67 | ||||
Number Of Employees | 20 | ||||
Beta | 0.57 | ||||
Market Capitalization | 13.71 M | ||||
Total Asset | 44.3 M | ||||
Retained Earnings | (137.45 M) | ||||
Working Capital | 8.61 M | ||||
Net Asset | 44.3 M |
About Purple Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Purple Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Purple Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Purple Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Purple Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Purple Biotech Piotroski F Score and Purple Biotech Altman Z Score analysis. For more information on how to buy Purple Stock please use our How to Invest in Purple Biotech guide.Note that the Purple Biotech information on this page should be used as a complementary analysis to other Purple Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Purple Stock analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Transaction History View history of all your transactions and understand their impact on performance | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Purple Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Purple Biotech. If investors know Purple will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Purple Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Purple Biotech is measured differently than its book value, which is the value of Purple that is recorded on the company's balance sheet. Investors also form their own opinion of Purple Biotech's value that differs from its market value or its book value, called intrinsic value, which is Purple Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Purple Biotech's market value can be influenced by many factors that don't directly affect Purple Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Purple Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Purple Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Purple Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.